Related content

Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome

By Sales MF   Sóter MO   Candido AL   Fernandes AP   Oliveira FR   Ferreira ACS   Sousa MO   Ferreira CN   Gomes KB  

Gynecological Endocrinology, Vol. 29, Iss. 10, 2013-10 ,pp. : 936-939

Informa Healthcare

Access to resources Recommend Favorite

Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system

By Sills E. Scott   Drews C. D.   Perloe M.   Tucker M. J.   Kaplan C. R.   Palermo G. D.  

Gynecological Endocrinology, Vol. 17, Iss. 3, 2003-06 ,pp. : 231-237

Informa Healthcare

Access to resources Recommend Favorite

Molecular Advances in Plasminogen Activator Inhibitor 1 Interaction with Thrombin and Tissue-Type Plasminogen Activator

By Stoop A.   van Meijer M.   Horrevoets A.J.G.   Pannekoek H.  

Trends in Cardiovascular Medicine, Vol. 7, Iss. 2, 1997-02 ,pp. : 47-51

Elsevier

Access to resources Recommend Favorite

Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy

By Agirbasli Mehmet  

Journal of Thrombosis and Thrombolysis, Vol. 32, Iss. 1, 2011-07 ,pp. : 59-63

Springer Publishing Company

Access to resources Recommend Favorite

Impact of intraperitoneal pressure and duration of surgery on levels of tissue plasminogen activator and plasminogen activator inhibitor-1 mRNA in peritoneal tissues during laparoscopic surgery

By Matsuzaki Sachiko   Botchorishvili Revaz   Jardon Kris   Maleysson Elodie   Canis Michel   Mage Gérard  

Human Reproduction, Vol. 26, Iss. 5, 2011-05 ,pp. : 1073-1081

Oxford University Press

Access to resources Recommend Favorite